Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTV01E Booster in mRNA Vaccinated Adults
NCT05238441Phase 2Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Mar 2022
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, double-blind trial of SCTV01E in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Sinocelltech Group Limited. Primary endpoint: Geometric Mean Titer of Neutralizing Antibodies against Delta Variant at Day 208. Status: unknown.
02
Drugs
SCTV01E
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05238441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238441.